- E-mailRakel.Forthun@uib.no
- Phone+47 55 58 45 11+47 414 59 638
- Visitor AddressHaukeland universitetssykehus, LaboratoriebyggetRoomArmauer Hansens hus, rom 008
- Postal AddressPostboks 78045020 Bergen
My main field of interest is proteomic analyses of novel therapeutic combinations for the treatment of Acute Myeloid Leukemia (AML). In this project, my main focus is to find new drugs and chemicals that can complement and increase the anti-leukemic effect of valproic acid, and to discover the mechanisms behind this effect.
Cross-species functional genomic analysis identifies resistance genes of the histone deacetylase inhibitor valproic acid.
Forthun RB, Sengupta T, Skjeldam HK, Lindvall JM, McCormack E, Gjertsen BT, Nilsen H.
PLoS One. 2012
Synergistic induction of p53 mediated apoptosis by valproic acid and nutlin-3 in acute myeloid leukemia.
McCormack E, Haaland I, Venås G, Forthun RB, Huseby S, Gausdal G, Knappskog S, Micklem DR, Lorens JB, Bruserud O, Gjertsen BT.
Leukemia. 2012
Clinical proteomics of myeloid leukemia.
Hjelle SM, Forthun RB, Haaland I, Reikvam H, Sjøholt G, Bruserud O, Gjertsen BT.
Genome Med. 2010
• Master degree in medical cell biology, "A phosphoproteomic study of the Theophylline-Valproic acid-ATRA combination therapy in the BNML rat model" 2008
• PhD, "Phosphoproteomics in disease stratification and therapy design of acute myeloid leukemia", 2012